Wang et al. [55] indicated that PD-1 AS isoforms b should be considered a biomarker for clinical responsiveness to anti-PD-1/PD-L1 immunotherapy; isoform c had a prometastatic role and is a new potential target for colorectal cancer therapy. Here, PDCD1 is linked to colorectal cancer.